Having brought a major revolution in the weight loss drugs market, Rimonabant better known as Acomplia now is a sigh of relief for patients suffering from type 2 diebetes in addition to obese populace. Fabricated by the French pharmaceutical giant Sanofi-Aventis, the marvelous preparation has an atypical potential to reduce body weight simultaneously with blood fats and blood glucose in people with type 2 diabetes, as per the study published by the British health journal, The Lancet.

Type 2 diabetes is a potentially severe disease which commonly emerges at the stage of adulthood. In the past two decades, the total number of people falling prey to this intimidating disease has escalated on an alarming rate. And obesity, high levels of harmful cholesterol and high blood pressure are few risk-factors that have been shoring up type2 diabetes patient’s graph every year.

Under the study sponsored by the Rimonabant diet pills maker, Sanofi-Aventis and conducted over 1,047 obese diabetes patients and overweight in 11 countries including Europe, North and South America, the effectiveness of Rimonabant weight loss pills was tested and compared with an analogous weight loss pill called Placebo for one year. In the conclusion, patients who were making use of rimonabant lost more weight when compared with Placebo users. In addition they also reported remarkable improvement in their appetite and blood glucose level than the Placebo users. Although Rimonabant diet pills were well endured by most, but few patients have complained about the onset of anxiety, nausea, and vomiting.

The study definitely is a major landmark considering the dearth of a real-time solution for type 2 diabetes at present. As all available drugs only can improve the blood glucose and lead to weight gain simultaneously, Rimonabant diet pills will be a credible alternative to keep type 2 diabetes in control.